• SHOP
    • COMBOS
    • TESTIMONIALS
    • CART
    • INGREDIENTS
      • 2-DEOXY-D-GLUCOSE (2DG)
      • ACACIA CYANOPHYLLA FLOWER
      • ACORI GRAMINEI RHIZOMA
      • AEGLE MARMELOS CORREA
      • AGARICUS BLAZEI
      • AGED GARLIC EXTRACT
      • AFRAMOMUM MELEGUETA
      • ALOE ARBORESCENS
      • ALBIZIA
      • ALPINIA OFFICINARUM
      • ALTERNANTHERA SESSILIS
      • AMERICAN GINSENG
      • AMYGDALIN
      • ANACYCLUS PYRETHRUM
      • ANGELICA ARCHANGELICA
      • ANGELICA SINENSIS
      • ANTRODIA
      • APIGENIN
      • ARTICHOKE LEAF
      • ARTOCARPIN
      • AJUGA TURKESTANICA
      • ASHWAGANDHA
      • ASPALATHIN
      • ASTRAGALUS COMPLANATUS
      • AVENA SATIVA
      • BACOPA MONNIERI
      • BAVACHIN
      • BEE POLLEN
      • BETULINIC ACID
      • BOSWELLIC ACID
      • BREVILIN A
      • CAMPESTEROL
      • CAPSAICIN
      • CARCININE
      • CASTICIN
      • CHRYSIN
      • CIANIDANOL
      • CINNAMOMUM ZEYLANICUM
      • CITRULLUS COLOCYNTHIS
      • CITRUS RETICULATA PEEL
      • CODONOPSIS
      • CONJUGATED LINOLEIC ACID
      • COSTUNOLIDE
      • CYANIDIN
      • CUCURBITACIN D
      • DAIDZEIN
      • DECURSIN
      • DELPHINIDIN
      • DIGITALIS PURPREA (DIGOXIN)
      • DIOSMIN
      • ELLAGIC ACID
      • EMBELIN
      • ERIODICTYOL
      • GALLIC ACID
      • GLYCITEIN
      • GLYCYRRHIZIN
      • HYPERFORIN
      • ICARIIN
      • ISORHAMNETIN
      • ISOORIENTIN
      • ISOVITEXIN
      • JACEOSIDIN
      • KAEMPFEROL
      • KIGELIA AFRICANA
      • KURARINONE
      • LEMON BALM
      • LICORICIDIN
      • LIPOIC ACID
      • LUPEOL
      • MAGNOLOL
      • MENAQUINONE 4
      • MULBERRY LEAF
      • NARINGENIN
      • NOBILETIN
      • OLEACEIN
      • OLEANOLIC ACID
      • OLIVE OIL
      • ORIDONIN
      • PARTHENOLIDE
      • PHLOROGLUCINOL
      • PHLORIZIN
      • PICEATANNOL
      • PRISTIMERIN
      • PROANTHOCYANIDINS
      • PROCYANIDIN B3
      • PSEUDOLARIC ACID B
      • PTEROSTILBENE
      • RUTIN
      • SOLIDAGO VIRGAUREA
      • TANGERETIN
      • TARAXASTEROL
      • TRICHOSTATIN A
      • WEDELOLACTONE
      • WOGONIN
      • YERBA MATE
    • ABOUT
    • SCIENTIFIC STUDIES
      • ADAPTOGENS
      • ADIPOCYTE APOPTOSIS (KILLING FAT CELLS)
      • ADDICTION & THE BRAIN
      • ADDICTION & STRESS
      • ADDICTION WITHDRAWAL
      • ADIPOCYTE DEDIFFERENTIATION (THE REVERSAL OF FAT FORMATION)
      • ADIPOCYTE DIFFERENTIATION
      • ADROPIN
      • ALLERGIES & CYTOKINES
      • ALDOSTERONE & OBESITY/HYPERTENSION
      • ALZHEIMER’S, DEMENTIA, PARKINSON’S
      • ANTI-ACNE EFFECT OF FLAVONOIDS AND POLYPHENOLS
      • ADVANCED GLYCATION END PRODUCTS (AGES)
      • ADDICTION TREATMENT
      • ADDICTION & DOPAMINE
      • AMPK
      • ANTI AGING
      • ANTIAGING EFFECTS OF COFFEE
      • ANTI-AGING EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-APOPTOTIC PATHWAYS
      • ANTI ATHEROGENIC
      • ANTI-CANCER EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI CARIOGENIC (Protecting From Tooth Decay)
      • ANTI COVID-19 EFFECTS OF MEDICINAL PLANTS, FLAVONOIDS & POLYPHENOLS
      • ANTI GLYCATIVE
      • ANTI GLYCATION AGENTS
      • ANTI-INFLAMMATORY EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-VIRAL EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI WRINKLE AGENTS
      • ANXIOLYTIC
      • APOPTOSIS
      • APOPTOSIS IN 3T3-L1
      • AUTOPHAGY
      • BCL-2
      • BCL-W
      • BCL-XL
      • BDNF
      • BECLIN-1 & AUTOPHAGY
      • BH3 MIMETICS
      • BIM aka BCL2L11
      • BIOMIMETIC HYDROXYAPATITE
      • BMI-1
      • BPA & OBESITY
      • BRASSINOSTEROIDS
      • CALORIE RESTRICTION
      • CALORIE RESTRICTION & LIFESPAN EXTENSION
      • CARBAMYLATION
      • CARBONYL SCAVENGER
      • CARBONYL STRESS
      • CARDIOPROTECTIVE AGENTS
      • CARDIAC GLYCOSIDES
      • CATALASE
      • CELL CYCLE ARREST
      • CENTENARIANS
      • CDK5
      • CHOLESTEROL EFFLUX
      • COGNITIVE ENHANCEMENT
      • COLD SHOCK PROTEINS
      • COLD-INDUCIBLE RNA-BINDING PROTEIN (CIRBP) & DNA REPAIR
      • CONDITIONED PLACE PREFERENCE
      • CORTICOTROPIN RELEASING FACTOR
      • CRYOTHERAPY
      • CRYOLIPOLYSIS: FREEZING FAT TO DEATH
      • CYP2E1
      • CYTOKINES IN PAIN, INFLAMMATION & AGING
      • DAF-16
      • DEPERSONALIZATION
      • DIABETES & CANCER
      • DIHYDROTESTOSTERONE (DHT)
      • DNA METHYLATION & AGING
      • DNA REPAIR
      • DNA REPAIR VIA FLAVONOIDS & POLYPHENOLS
      • DRY FASTING AND FLUID RESTRICTION FASTING
      • DYNORPHIN
      • ELLAGITANNINS
      • ENDOCRINE DISRUPTING CHEMICALS
      • ENLARGED HEART AND CARDIOMEGALY
      • EPIGENETIC MODIFIERS
      • EPINEPHRINE
      • ERGOGENIC AGENTS (INCREASE ATHLETIC PERFORMANCE)
      • EXCITOXICITY & THE BRAIN
      • EXTRACELLULAR MATRIX STIFFENING (10TH HALLMARK OF AGING)
      • EXTENDS LIFESPAN
      • EXTINCTION TRAINING
      • FASTING & THE BRAIN
      • FASTING & CANCER
      • FASTING MIMICKING DIET
      • FEAR EXTINCTION
      • FGF21
      • FLAVONES
      • GABA (γ-AMINOBUTYRIC ACID)
      • GALLOTANNINS
      • GLUCONEOGENESIS
      • GLUCOCORTICOID RECEPTOR ACTIVATION
      • GLUTAMATE & BRAIN
      • GLYCATION
      • GUT BRAIN AXIS
      • KLOTHO
      • K OPIOD RECEPTOR & ADDICTION
      • FASTING, CALORIE RESTRICTION & EXTENDING LIFESPAN
      • FOXO3
      • FOXO4
      • HALLMARKS OF AGING
      • HAIR REPIGMENTATION
      • HEPATOPROTECTIVE AGENTS (KEEPING LIVER HEALTHY)
      • HMGB1
      • HORMESIS
      • HPA AXIS
      • HSP70, THE ANTI-AGING PROTEIN
      • HSP90 INHIBITORS
      • HYPERGLYCEMIA
      • HYPERALGESIA
      • HYPERINSULINEMIA
      • HYPOTHALAMIC PITUITARY ADRENAL HPA AXIS
      • HYPOACTIVE SEXUAL DESIRE (WHY PEOPLE HAVE ZERO SEX DRIVE)
      • HYPOCRETIN OREXIN
      • IKK
      • IL-6/STAT3
      • IRISIN
      • ISOFLAVONES
      • IMMUNOSENESCENCE
      • INCREASE PROTEIN SYNTHESIS
      • INFECTOBESITY
      • INFLAMMATION & ANXIETY
      • INFLAMMATION & CANCER
      • INFLAMMATION & DEPRESSION
      • INFLAMMATION & OBESITY
      • INFLAMMAGING
      • INHIBITION OF RENAL GLUCOSE REABSORPTION
      • INSULIN & AGING
      • INSULIN & CANCER: HOW INSULIN LITERALLY PROTECTS CANCER CELLS FROM BEING KILLED
      • INSULIN & MTOR
      • INSULIN & OBESITY
      • INSULIN OXIDATIVE STRESS
      • INTERMITTENT FASTING
      • JAK INHIBITION ALLEVIATES SASP
      • JNK ACTIVATION PREVENTS PREMATURE SENESCENCE
      • KETONE BODIES
      • KETOGENIC DIET
      • LEYDIG CELL STEROIDOGENESIS
      • LIFESPAN EXTENSION
      • LIPOLYTIC AGENTS
      • LIPID DROPLETS
      • LIPOLYSIS (THE DECOMPOSITION OF BODY FAT)
      • LOWERING CHOLESTEROL THRU FASTING, DIET & MEDICINAL PLANTS
      • MATRIX METALLOPROTEINASES (MMPs)
      • MCL-1
      • MDM2 INHIBITION AS SASP INHIBITOR
      • MEDITERRANEAN DIET
      • METABOLIC REPROGRAMMING
      • METABOLIC SYNDROME
      • METHIONINE RESTRICTION
      • MITOCHONDRIAL UNCOUPLING
      • MONKEYPOX
      • MSG (MONOSOSODIUM GLUTAMATE)
      • MUSCLE FORCE PRODUCTION
      • MUSCLE ATROPHY (PREVENTING)
      • MYOGENESIS
      • MYOSTATIN INHIBITION
      • MYOSTATIN INHIBITION PRESERVES MUSCLE
      • mTORC2
      • mTOR: THE RAPID AGING PATHWAY
      • NATURAL ANTICOAGULANTS
      • NATURAL AROMATASE INHIBITORS
      • NEUROGENESIS (GROWING NEW BRAIN CELLS)
      • NEUROCHEMISTRY OF ADDICTION
      • NEUROPLASTICITY
      • NEUROINFLAMMATION
      • NEUROPROTECTIVE AGENTS
      • NEUTRALIZING OXIDATIVE STRESS WITH MEDICINAL PLANTS
      • NMDA & ANXIETY & DEPRESSION
      • NMDA RECEPTOR & FEAR
      • NON OPIOD ANALGESICS
      • NOOTROPICS
      • NORADRENERGIC
      • NOREPINEPHRINE
      • NRF2: MASTER REGULATOR OF THE AGING PROCESS
      • NF-KB
      • OBESOGENS
      • ONCOGENE ACTIVATION INDUCED SENESCENCE
      • OVERNUTRITION
      • OXIDATIVE STRESS & AGING
      • P16INK4A
      • P38MAPK
      • P53: TUMOR SUPRESSOR
      • PERIODONTITIS
      • PHYTOCHEMICALS
      • PHYTOSTEROLS
      • PHYTOSTANOLS
      • PHYTOECDYSTEROIDS
      • PROANTHOCYANIDINS
      • PROTEIN CARBONYLATION
      • POLYAMINES & THEIR EFFECT ON BRAIN (NMDA, DEPRESSION, SUICIDE RISK)
      • POLYPHENOLS AS COVID-19 TREATMENT & PREVENTION
      • PPARY2
      • PREMATURE SENESCENCE
      • PREVENTING SKIN AGING
      • PUFAS
      • PURGATIVES
      • RAPAMYCIN (MTOR INHIBITION)
      • RED WINE
      • RENAL (KIDNEY) PROTECTIVE AGENTS
      • REMINERALIZATION OF TEETH
      • REPAIR OF DNA BREAKS “DOUBLE STRAND”
      • RESTORE INSULIN SENSITIVITY
      • SASP & ADIPOSE TISSUE
      • SEX HORMONE BINDING GLOBULIN
      • SENESCENT CELLS, SASP & SENOLYTICS
      • SENESCENCE-BETA-GALACTOSIDASE (SA-β-gal or SABG)
      • SGLT2 INHIBITORS
      • SGLT2 INHIBITION FOR LIFESPAN EXTENSION
      • SHBG
      • SIRT1
      • SKELETAL MUSCLE HYPERTROPHY (THE SCIENCE OF BUILDING MUSCLE)
      • SKIN ELASTICITY
      • SKIN PHOTOAGING (Preventing & Repairing)
      • SLEEP DEPRIVATION AS THERAPY FOR DEPRESSION
      • SIRT1 & LONGEVITY
      • SMALLPOX
      • SUGAR & AGING
      • STAR PROTEIN
      • STAT3
      • STEM CELL EXHAUSTION
      • STEM CELL REGENERATION
      • STEM CELL THERAPY
      • STIMULATED LIPOLYSYS
      • STEROIDOGENESIS (THE PRODUCTION OF HORMONES IN BODY)
      • STREPTOCOCCUS MUTANS (MAIN BACTERIA BEHIND TOOTH DECAY)
      • STRESS & AGING
      • STRESS & THE BRAIN
      • TELOMERE SHORTENING & PREMATURE AGING
      • TIME RESTRICTED FEEDING
      • THROMBOLYTICS (PLANT BASED)
      • TRAUMATIC BRAIN INJURY (HEALING)
      • TRYPTOPHAN HYDROXYLASE 2
      • VISCERAL ADIPOSITY
      • XENOBIOTICS
      • XENOESTROGEN
    • HOME
    • CONTACT
    • INTERSTELLAR 88/8: EXTREME WEIGHTLOSS PROTOCOL
    • The Ultimate Dry Fasting Resource
    0
    VISCERAL ADIPOSITY
    September 12, 2021
    ADIPOCYTE DIFFERENTIATION
    September 12, 2021
    1. SGLT inhibitors in management of diabetes
    2. Structural selectivity of human SGLT inhibitors
    3. A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized …
    4. SGLT inhibitors as antidiabetic agents: a comprehensive review
    5. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium–glucose cotransporter (SGLT) inhibitors
    6. SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects
    7. SGLT inhibitors for type 1 diabetes: proceed with extreme caution
    8. SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery
    9. Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: a STICH protocol
    10. SGLT inhibitors for type 1 diabetes: an obvious choice or too good to be true?
    11. The anti-inflammatory effects of SGLT inhibitors
    12. Na+-Glucose Cotransporter (SGLT) inhibitors as Antidiabetic Agents. 4. Synthesis and Pharmacological Properties of 4′-Dehydroxyphlorizin Derivatives Substituted …
    13. SGLT inhibitors as new therapeutic tools in the treatment of diabetes
    14. natural products as lead compounds for sodium glucose cotransporter (SGLT) inhibitors
    15. SGLT inhibitors for people with type 1 diabetes
    16. SGLT inhibitors: a novel target for diabetes
    17. Impact of SGLT inhibitors on Multiple Organ Defects in Diabetes.
    18. Effects of sodium‐glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: a meta …
    19. Pyrazole-O-glucosides as novel Na+-glucose cotransporter (SGLT) inhibitors
    20. Synthesis of isotopically labelled SGLT inhibitors and their metabolites
    21. Cyclic diarylheptanoids as Na+-glucose cotransporter (SGLT) inhibitors from Acer nikoense
    22. A quantitative systems pharmacology kidney model of diabetes associated renal hyperfiltration and the effects of SGLT inhibitors
    23. QSAR studies on triazole derivatives as SGLT inhibitors via CoMFA and CoMSIA
    24. Diabetic proximal tubulopathy: Can we mimic the disease for in vitro screening of SGLT inhibitors?
    25. The bark giving diabetes therapy some bite: the SGLT inhibitors
    26. Effect of SGLT inhibitors on weight and lipid metabolism at 24 weeks of treatment in patients with diabetes mellitus: A systematic review and network meta …
    27. Synthesis of L-rhamnose derived chiral bicyclic triazoles as novel sodium-glucose transporter (SGLT) inhibitors
    28. SGLT inhibitors and euglycaemic diabetic ketoacidosis: earlier observations rediscovered
    29. Commentary: SGLT inhibitors in type 1 diabetes: Place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis‐the STOP DKA protocol
    30. Synthesis of novel l-rhamnose derived acyclic C-nucleosides with substituted 1, 2, 3-triazole core as potent sodium-glucose co-transporter (SGLT) inhibitors
    31. SGLT inhibitors for type 1 diabetes
    32. Factors that predict glycaemic response to sodium‐glucose linked transporter (SGLT) inhibitors
    33. The bark giving diabetes therapy some bite: the SGLT inhibitors
    34. SGLT inhibitors attenuate NO‐dependent vascular relaxation in mouse pulmonary artery (677.3)
    35. SGLT inhibitors for type 1 diabetes: a finely balanced matter?
    36. Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors
    37. Novel SGLT inhibitors (SGL5083 and SGL5085), Acting on Both Suppressing Intestinal Glucose Absorption and Increasing Urinary Glucose Excretion, Improve …
    38. SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids
    39. SGLT inhibitors Enhance Endogenous Glucose Productions (EGP) in a Preclinical Animal Model
    40. SAT-662 Effects of SGLT inhibitors or GLP1 Analogues on Glucose Homeostasis and Body Weight in Patients with Type 1 Diabetes: A Network Meta-Analysis
    41. Correction: Synthesis of l-rhamnose derived chiral bicyclic triazoles as novel sodium-glucose transporter (SGLT) inhibitors
    42. Sodium-glucose co-transporter (SGLT) inhibitors: a novel class of oral anti-diabetic drugs
    43. Synthesis of novel l-rhamnose derived acyclic C-nucleosides with substituted 1, 2, 3-triazole core as potent sodium-glucose co-transporter (SGLT) inhibitors
    44. Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
    45. Sodium–glucose cotransporter–2 (SGLT-2) inhibitors and the treatment of type 2 diabetes
    46. Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk
    47. … -2 inhibitors and cardiovascular protection: lessons and gaps in understanding the current outcome trials and possible benefits of combining SGLT-2 inhibitors …
    48. The effect of sodium-glucose co-transporter-2 (SGLT-2) inhibitors on cardiometabolic profile; beyond the hypoglycaemic action
    49. Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT‐2 inhibitors and GLP‐1 receptor agonists
    50. The Effects of DPP-4 inhibitors, GLP-1RAs, and SGLT-2/1 inhibitors on heart failure outcomes in diabetic patients with and without heart failure history …
    51. SGLT-2 inhibitors-hope or hype?-an updated review
    52. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and …
    53. The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 inhibitors and Pioglitazone
    54. PDB29 A COST-UTILITY ANALYSIS OF SODIUM-GLUCOSE COTRANSPORTER (SGLT) 2 inhibitors IN ADDITION TO BASAL-BOLUS INSULIN IN THE …
    55. Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic …
    56. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes
    57. Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in the perioperative setting
    58. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for cardiovascular disease prevention
    59. Management of type 2 diabetes mellitus in older adults: eight case studies with focus SGLT-2 inhibitors and metformin
    60. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis
    61. A novel SGLT-2 score to identify HFpEF patients who may benefit from SGLT-2 inhibitors
    62. Recent Advances on SGLT 2 inhibitors: Synthetic Approaches, Therapeutic Benefits, and Adverse Events
    63. Possible sodium-glucose cotransporter-2 (SGLT-2) inhibitors for reducing effects of blood glucose and also blood pressure
    64. Outcomes of patients with type 2 diabetes treated with SGLT-2 inhibitors versus DPP-4 inhibitors. An Italian real-world study in the context of other observational …
    65. SGLT 2 inhibitors: Antidiabetic agents with promising effects beyond glucose control
    66. Update on Cardiovascular Benefits with Sodium Glucose Cotransporter-2 inhibitors (SGLT-2i). On J Cardio Res & Rep. 1 (5): 2019
    67. Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors
    68. Sodium–glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class
    69. Sodium-glucose cotransporter Type 2 (SGLT-2) inhibitors and ketogenesis: The Good and the Bad
    70. A Case Report of Euglycemic Diabetic Ketoacidosis in the Setting of Keto Diet and SGLT-2 inhibitors
    71. Sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors and cancer: a meta‐analysis of randomized controlled trials
    72. 2232: Acute kidney injury in patients on SGLT-2 inhibitors: A propensity matched analysis
    73. Short and medium‐term efficacy of sodium glucose co‐transporter‐2 (SGLT‐2) inhibitors: A meta‐analysis of randomized clinical trials
    74. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials
    75. 480: COMPARISON OF TREATMENT OF KETOACIDOSIS ASSOCIATED WITH SGLT-2 inhibitors AND USUAL DKA
    76. Novel oral hypoglycemic agents SGLT-2 inhibitors: cardiovascular benefits and potential mechanisms
    77. Management of type 2 diabetes mellitus with overweight: Focus on SGLT-2 inhibitors and GLP-1 receptor agonists
    78. Can sodium glucose cotransporter 2 (SGLT-2) inhibitors be beneficial in patients with acute myocardial infarction?
    79. … Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis
    80. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes
    81. Comparable COVID‐19 outcomes with current use of GLP‐1 receptor agonists, DPP‐4 inhibitors or SGLT‐2 inhibitors among patients with diabetes who tested …
    82. Peripheral artery disease and amputations with Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials
    83. Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduce hospitalization for heart failure only and have no effect on atherosclerotic cardiovascular events …
    84. SGLT-2 inhibitors and peripheral artery disease: a statistical hoax or reality?
    85. Use of Sodium–Glucose Cotransporter 2 (SGLT-2) inhibitors Beyond Diabetes: On the Verge of a Paradigm Shift?
    86. An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors
    87. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study
    88. SGLT-2 inhibitors: a new mechanism for glycemic control
    89. Blood pressure-lowering effect of newer antihyperglycemic agents (SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors)
    90. SGLT-2 inhibitors as second-line therapy in type 2 diabetes.
    91. In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes
    92. SAT-685 Euglycemic Diabetic Ketoacidosis in T1d: The Era of SGLT-2 inhibitors and Keto-Diet
    93. SGLT‐2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects
    94. The kidney as a new target for antidiabetic drugs: SGLT 2 inhibitors
    95. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta …
    96. Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment
    97. Dynamics of epicardiac fat and heart function in type 2 diabetic patients initiated with SGLT-2 inhibitors
    98. The safety of dipeptidyl peptidase‐4 (DPP‐4) inhibitors or sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors added to metformin background therapy in patients with …
    99. Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience
    100. Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes
    101. Diabetic ketoacidosis in patients with type 2 diabetes recently commenced on SGLT-2 inhibitors: an ongoing concern
    102. 194 SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes
    103. Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes
    104. SGLT-2 inhibitors were not linked to severe or nonsevere UTIs vs DPP-4 inhibitors or GLP-1 agonists
    105. GLP-1 receptor agonists versus SGLT-2 inhibitors in obese type 2 diabetes patients
    106. Off-label prescription of SGLT-2 inhibitors to patients with type 1 diabetes: an online survey of diabetes specialists in Italy
    107. The mechanisms and clinical potential: sodium-glucose cotransporter 2 (SGLT-2) inhibitors treating diabetic kidney disease
    108. SGLT 2 inhibitors; glycemic control, weight loss and safety profile in patients with type 2 Diabetes, at Medicell Institute (MIDEM)
    109. Nephrolithiasis and sodium-glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials
    110. The role of SGLT-2 inhibitors in the treatment of type 2 diabetes
    111. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials
    112. Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors
    113. Noninvasive monitoring of liver fat during treatment with GLP‐1 analogues and SGLT‐2 inhibitors in a real‐world setting
    114. Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study.
    115. Ambulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide
    116. SGLT-2 inhibitors and GLP-1 agonists: first-line therapy for diabetes with established cardiovascular disease
    117. The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes
    118. A systematic review and meta-analysis of the impact of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiovascular outcomes in biologically healthy …
    119. GLP-1 Agonists and SGLT-2 inhibitors in Type 2 Diabetes Patients
    120. Short-and medium-term efficacy of sodium glucose cotransporter 2 (SGLT-2) inhibitors for the treatment of type 1 diabetes: systematic review and meta-analysis
    121. MON-690 Euglycemic Diabetic Ketoacidosis Associated with SGLT-2 inhibitors-an Under-recognized Diagnosis
    122. … and biological evaluation of (2S, 3R, 4R, 5S, 6R)-5-fluoro-6-(hydroxymethyl)-2-aryltetrahydro-2H-pyran-3, 4-diols as potent and orally active SGLT dual inhibitors
    123. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus …
    124. Does gender influence the cardiovascular benefits observed with sodium glucose co-transporter-2 (SGLT-2) inhibitors? A meta-regression analysis
    125. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors for patients with Type 2 diabetes
    126. Rates of myocardial infarction and stroke in patients initiating treatment with SGLT 2‐inhibitors versus other glucose‐lowering agents in real‐world clinical practice: R …
    127. … agents in type 1 diabetes in addition to insulin therapy: metformin, alpha-glucosidase inhibitors, pioglitazone, GLP-1 agonists, DPP-IV inhibitors, and SGLT-2 inhibitors
    128. Efficacy and Safety of SGLT-2 inhibitors for Treatment of Diabetes Mellitus among Kidney Transplant Patients: A Systematic Review and Meta-Analysis
    129. SGLT-2 inhibitors: is there a role in type 1 diabetes mellitus management?
    130. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: a review of the clinical evidence
    131. SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL
    132. How do SGLT-2 inhibitors work to prevent heart failure?
    133. SGLT-2 inhibitors as adjunctive to insulin therapy in type 1 diabetes
    134. SGLT 2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature
    135. Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a …
    136. Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 inhibitors
    137. 4111 Association of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors with cardiovascular events stratified by renal function: a network meta-analysis
    138. SGLT-2 inhibitors in heart failure: implications for the kidneys
    139. SGLT-2 inhibitors and their potential in the treatment of diabetes
    140. Emerging role of SGLT-2 inhibitors for the treatment of obesity
    141. SGLT 2 inhibitors act from the extracellular surface of the cell membrane
    142. Safe and pragmatic use of sodium-glucose co-transporter 2 (SGLT 2) inhibitors: medication counseling
    143. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
    144. SAFETY ISSUES WITH THE USE OF SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT-2) inhibitors
    145. Re: diabetic ketoacidosis in patients with type 2 diabetes on SGLT-2 inhibitors: an ongoing concern
    146. SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: a systematic review and meta-analysis of retrospective cohort studies
    147. SGLT‐2 inhibitors and the risk of lower‐limb amputation: is this a class effect?
    148. … Compounds against Type 2 Diabetes Mellitus: Proof of Concept for Sodium Dependent Glucose Transporter (SGLT) and Glycogen Phosphorylase (GP) inhibitors
    149. SGLT-2 inhibitors: potential novel strategy to prevent congestive heart failure in diabetes?
    150. Effects of SGLT-2 inhibitors on diabetic ketoacidosis: a meta-analysis of randomised controlled trials
    151. Structure–Activity Relationship Study of Acyclic Terpenes in Blood Glucose Levels: Potential α-Glucosidase and Sodium Glucose Cotransporter (SGLT-1) inhibitors
    152. Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitors: Benefits in Diabetics With Cardiovascular Disease
    153. Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation
    154. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review
    155. A look to the future in non-alcoholic fatty liver disease: Are GLP-1 analogues or SGLT-2 inhibitors the answer?
    156. Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in type 1 diabetes
    157. P2519 Comparison of SGLT-2 inhibitors, GLP-1 agonist and DPP-4 inhibitors for mortality outcomes in participants with type 2 diabetes: a network meta-analysis of 96 …
    158. Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors
    159. Effects of GLP-1 Receptor Agonists and SGLT-2 inhibitors in Heart Transplant Patients with Type 2 Diabetes: a Case Series
    160. Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials
    161. The beneficial hemodynamic actions of SGLT-2 inhibitors beyond the management of hyperglycemia
    162. Sodium–glucose co-transporter-2 (SGLT-2) inhibitors in patients with type 2 diabetes mellitus: the road ahead
    163. Combination of SGLT-2 inhibitors and GLP-1 receptor agonists: potential benefits in surrogate and hard endpoints
    164. Class effect for SGLT-2 inhibitors: a tale of 9 drugs
    165. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors in heart transplant patients with type 2 diabetes: Initial report from a cardiometabolic center of excellence
    166. Do the SGLT-2 inhibitors offer more than hypoglycemic activity?
    167. Adverse effects and safety of SGLT-2 inhibitors
    168. New diabetes therapies and diabetic kidney disease progression: the role of SGLT-2 inhibitors
    169. 66 Acute coronary syndrome in type 2 diabetes treated using SGLT-2 inhibitors, GLP-1 agonists and DPP-4 inhibitors: a comparative network meta-analysis of …
    170. Long-term effectiveness and safety of SGLT-2 inhibitors in an Italian cohort of patients with type 2 diabetes mellitus
    171. Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart …
    172. Sodium Glucose Co-Transporter 2 (SGLT-2) inhibitors: A Review
    173. Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive …
    174. 1233-P: Systematic Literature Review (SLR) and Network Meta-analysis (NMA) of SGLT-1/2 inhibitors vs. Metformin (MET) as Add-On to Insulin in T1DM
    175. 301P Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for alpelisib (ALP)-induced hyperglycemia: A report of 6 cases from SOLAR-1
    176. Comparison in Methods Between National Institute for Health And Care Excellence (Nice) Submissions For Sodium-Glucose Co-Transporter 2 inhibitors (SGLT-2i …
    177. The different hypoglycemic effects between East Asian and non-Asian type 2 diabetes patients when treated with SGLT-2 inhibitors as an add-on treatment for …
    178. Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic …
    179. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline
    180. SGLT-2 inhibitors for COVID-19—A miracle waiting to happen or just another beat around the bush?
    181. Early initiation of sodium‐glucose linked transporter inhibitors (SGLT‐2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients
    182. SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives
    183. Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies
    184. Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis
    185. An updated perspective and pooled analysis of cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors
    186. SGLT-2 inhibitors may be targeting higher risk patients with diabetes possibly justifying higher cost: Single center repeated cross-sectional analysis
    187. Association Between Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitors and Lower Extremity Amputation: A Retrospective Cohort Study
    188. Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?
    189. SGLT-2 inhibitors in heart failure and type-2 diabetes: hitting two birds with one stone?
    190. SGLT-2 inhibitors: a novel mechanism in targeting glycemic control in type 2 diabetes mellitus
    191. Are SGLT-2 inhibitors the future of heart failure treatment? The EMPEROR-Preserved and EMPEROR-Reduced trials
    192. The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio-and nephroprotection
    193. SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions
    194. Use of SGLT-2 inhibitors in patients with type 2 diabetes mellitus and abdominal obesity: an Asian perspective and expert recommendations
    195. Elements for Success in Managing Type 2 Diabetes With SGLT-2 inhibitors: Role of the Kidney in Glucose Homeostasis: Implications for SGLT-2 Inhibition in the …
    196. The role of SGLT-2 inhibitors as part of optimal medical therapy in improving cardiovascular outcomes in patients with diabetes and coronary artery disease
    197. Best practices for safe use of SGLT-2 inhibitors developed from an expert panel Delphi consensus process
    198. SGLT-2 inhibitors: diabetes treatment by glycosuria; literature review on the effect of dapagliflozin
    199. Sodium glucose cotransporter (SGLT)‐2 inhibitors: Do we need them for glucose‐lowering, for cardiorenal protection or both?
    200. SGLT-2 inhibitors and cardiovascular risk in diabetes mellitus: a comprehensive and critical review of the literature
    201. Liraglutide versus SGLT-2 inhibitors in people with type 2 diabetes: a network meta-analysis
    202. SGLT-2 receptor inhibitors: An opportunity to revise our therapeutic strategy for type 2 diabetes?
    203. SGLT-2 inhibitors: their pleiotropic properties
    204. Diabetes Consultations™: Beyond Insulin: The Role of SGLT-2 inhibitors in Care of Patients with T1DM
    205. In patients with uncontrolled type 2 diabetes, are GLP-1 agonists more effective than SGLT-2 inhibitors in lowering HbA1c?
    206. Incretin based therapies and SGLT-2 inhibitors in kidney transplant recipients with diabetes: A systematic review and meta-analysis
    207. The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
    208. Challenges in simultaneous extraction and chromatographic separation of metformin and three SGLT-2 inhibitors in human plasma using LC–MS/MS
    209. CHARACTERISTICS OF PATIENTS INITIATING SODIUM GLUCOSE COTRANSPORTER-2 inhibitors (SGLT-2I) COMPARED TO PATIENTS INITIATING OTHER …
    210. SGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction
    211. Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: a systematic review and meta-analysis of cardio …
    212. SGLT-2 inhibitors reduce glucose absorption from peritoneal dialysis solution by suppressing the activity of SGLT-2
    213. SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort
    214. SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
    215. SGLT-2 inhibitors and DPP-4 inhibitors as second-line drugs in patients with type 2 diabetes: a meta-analysis of randomized clinical trials
    216. Renal benefits of SGLT 2 inhibitors and GLP-1 receptor agonists: evidence supporting a paradigm shift in the medical management of type 2 diabetes
    217. Cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in Asians with type 2 diabetes: a systematic review and meta-analysis of cardiovascular …
    218. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney …
    219. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic …
    220. Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists
    221. Sodium-Glucose Cotransporter 2 (SGLT-2) inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes …
    222. Let’s Be More Sensitive—How SGLT-2 inhibitors and GLP-1 Receptor Agonists Affect β-Cell Function in Type 2 Diabetes: Comment on “Improved Beta Cell Glucose …
    223. Letter by Tampaki et al Regarding Article,“Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 inhibitors”
    224. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized …
    225. Does background metformin therapy influence the cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes?
    226. Toe amputations with SGLT-2 inhibitors: data from randomized clinical trials
    227. SGLT-2 inhibitors in diabetes: a focus on renoprotection
    228. Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational …
    229. The placebo response of injectable GLP‐1 receptor agonists vs. oral DPP‐4 inhibitors and SGLT‐2 inhibitors: a systematic review and meta‐analysis
    230. Mechanisms for Cardiorenal Protection of SGLT-2 inhibitors
    231. Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus
    232. SGLT-2 inhibitors in development for type 2 diabetes treatment
    233. SGLT-2 inhibitors in type 1 diabetes mellitus: a comprehensive review of the literature
    234. Cardiovascular effects of SGLT‐2 inhibitors: What we have learned from cardiovascular outcome trials and what we still need to understand
    235. Response to letter:’Acute heart failure, type 2 diabetes and loop diuretic use: any adjunct role for SGLT-2 inhibitors?’
    236. Efficacy in metabolic control and weight loss of combined treatment with GLP-1 receptor analogues and SGLT-2 inhibitors
    237. SGLT-2 inhibitors in heart failure: A new therapeutic avenue
    238. Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management
    239. SGLT-2 inhibitors to treat hyponatremia associated with SIADH: a novel indication?
    240. Do SGLT‐2 inhibitors exhibit similar cardiovascular benefit in patients with heart failure with reduced or preserved ejection fraction?
    241. Differentiating Among the SGLT-2 inhibitors: Considering Cardiovascular and Other Safety Outcomes
    242. … -transporter 2 inhibitors and serum uric acid: Re: Mende CW. Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors …
    243. Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors
    244. Sodium-Glucose Co-Transporter-2 (SGLT-2) inhibitors And The Risk of Fractures of The Upper or Lower Limb In Patients With Type 2 Diabetes: A Nested-Case …
    245. Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin
    246. Antidiabetic SGLT-2 inhibitors prevent progression of chronic kidney disease
    247. The use of SGLT-2 inhibitors in type 2 diabetes and heart failure
    248. Hospitalization for Heart Failure and Death in New Users of SGLT-2 inhibitors in Patients With and Without Cardiovascular Disease—CVD Real Study
    249. A Role for SGLT-2 inhibitors in Treating Non-diabetic Chronic Kidney Disease
    250. Effect of background insulin therapy on cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes: A meta-analysis of cardiovascular outcome trials
    251. The role of self-monitoring of blood glucose in patients treated with SGLT-2 inhibitors: a European expert recommendation
    252. Sodium‐glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the …
    253. Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview
    254. Limitations of natriuretic peptide levels in establishing SGLT-2 inhibitors for heart failure care
    255. Prevention of cardiac allograft vasculopathy–A new possible indication for SGLT-2 inhibitors?
    256. SGLT-2 inhibitors as cardioprotective agents in COVID-19
    257. Challenges in Implementing Evidence Based Cross-Disciplinary Therapies: Are Cardiovascular Specialists Ready to Claim SGLT-2 inhibitors and GLP-1 Analogs?
    258. SGLT-2 inhibitors Use in Renal Transplant Patients with Diabetes: A Brief Review of the Current Literature.
    259. Lower Risk of Cardiovascular Events and Death Associated with Initiation of SGLT-2 inhibitors versus Other Glucose Lowering Drugs-Real World Data Across …
    260. SGLT-2 inhibitors Beneficial Effects on Ventricular Repolarization May Be Protective against Atrial Fibrillation Occurrence
    261. SGLT-2 inhibitors and regenerative cell exhaustion
    262. Clinical Spectrum and Mechanism of Acute Kidney Injury in Patients with Diabetes Mellitus on SGLT-2 inhibitors.
    263. SGLT-2 inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives
    264. The effect of SGLT‐2 inhibitors on mortality and heart failure in randomized trials versus observational studies
    265. … Effects of Central Nervous System Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Sodium Glucose Co-Transporter-2 inhibitors (SGLT …
    266. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 …
    267. SGLT‐2 inhibitors and the risk of hospitalization for community‐acquired pneumonia: A population‐based cohort study
    268. SGLT-2 inhibitors: Ideal Remedy for Cardioprotection in Diabetes Mellitus.
    269. Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a …
    270. Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes
    271. SGLT‐2 inhibitors and ketoacidosis: a disproportionality analysis in the World Health Organization’s adverse drug reactions database
    272. Translating the statistical benefits of SGLT-2 inhibitors on cardio-renal outcomes into clinical practice
    273. Perioperative euglycemic diabetic ketoacidosis following use of SGLT-2 inhibitors after cardiac surgery
    274. Effects of cardiovascular function of SGLT-2 inhibitos versus DPP-4 inhibitors in type 2 diabetes with coronary artery disease
    275. Can SGLT-2 inhibitors resolve the heart failure burden of diabetes mellitus-Is it empaglifozin or the class?
    276. SGLT-2 inhibitors in diabetic kidney disease: what lies behind their renoprotective properties?
    277. Efficacy of SGLT-2 inhibitors in older adults with diabetes: systematic review with meta-analysis of cardiovascular outcome trials
    278. Exploring the heterogeneity of the effects of SGLT-2 inhibitors in cardiovascular outcome trials
    279. … THE DIFFERENCES EFFECTS OF GLUCAGON LIKE PEPTIDE-1 (GLP-1) ANALOGUES AND SODIUM-COTRANSPORTER 2 (SGLT-2) inhibitors ON TYPE 2 …
    280. Dapagliflozin and renal function. Re: Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease …
    281. Effect of SGLT-2 inhibitors on non-alcoholic fatty liver disease among patients with type 2 diabetes mellitus: Systematic review with meta-analysis and trial …
    282. A study of the effects of SGLT-2 inhibitors on diabetic cardiomyopathy through miR-30d/KLF9/VEGFA pathway
    283. SGLT-2 inhibitors in Heart Failure: Volume or Value?
    284. SGLT-2 inhibitors users profile recruited through a pharmacy-based intensive monitoring study: analysis of the pharmacotherapeutic profile, drug-drug interactions …
    285. The role of SGLT-2 inhibitors in managing type 2 diabetes.
    286. Use of SGLT-2 inhibitors in Patients With Type 1 Diabetes Mellitus
    287. In Reply to ‘Do SGLT-2 inhibitors Act Only Through a Functional Tubuloglomerular Feedback Induced by the Increased Outflow of Sodium?’
    288. Postoperative euglycemic diabetic ketoacidosis and encephalopathy related to SGLT-2 inhibitors: a case report and discussion of diabetes treatment and “sweet pee …
    289. Trends in SGLT-2 inhibitors Usage in Heart Failure Patients With Type 2 Diabetes Mellitus, in a South-East Queensland Hospital
    290. SGLT-2 inhibitors for people with type 2 diabetes–Authors’ reply
    291. … and patient-centred outcome measures in randomized controlled trials conducted for diabetes pharmacotherapy: SGLT-2 receptor inhibitors as an example
    292. Implementing the treatment of heart failure with SGLT-2 inhibitors and sacubitril–valsartan: does money matter?
    293. SGLT-2 inhibitors: are they a promising treatment option in T2DM patients with NAFLD?
    294. Do SGLT-2 inhibitors reduce albuminuria in people with diabetes?
    295. Renal Effects of SGLT‐2 inhibitors and Other Anti‐diabetic Drugs: Clinical Relevance and Potential Risks
    296. Ketogenic Diets, Ketoacidosis and SGLT-2 inhibitors-Part 2..
    297. Chronic kidney disease and diabetes status do not affect efficacy of SGLT-2 inhibitors in patients with heart failure with reduced ejection fraction
    298. MON-602 The Efficacy and Safety of Sodium-Glucose Transport Protein 2 (SGLT-2) inhibitors for Weight Loss Among Individuals Without Diabetes: A Systematic …
    299. … Risk of Death and Cardiovascular Events in Unselected Type 2 Diabetes Patients Initiated on GLP-1 Receptor Agonists and SGLT-2 inhibitors in Two Large …
    300. SGLT-2 inhibitors—a Culprit of Diabetic Ketoacidosis Postbariatric Surgery
    301. Best practices for safe use of SGLT-2 inhibitors developed from an expert panel Delphi consensus process
    302. … Reporting and Data System Category 3 (Equivocal) Lesions Identified Infection and Inflammation of the Genitourinary Tract Re: SGLT-2 inhibitors and the Risk of …
    303. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus …
    304. Falls and SGLT-2 inhibitors in geriatric patients—A case report
    305. The Effect of SGLT-2 inhibitors and GLP-1 Agonists on Cardiovascular Disease in Patients with Type 2 Diabetes
    306. Systematic review and meta-analysis of the effect of SGLT-2 inhibitors on microvascular outcomes in patients with type 2 diabetes: a review protocol
    307. A Comprehensive Review on Analytical Method Development and Validation for SGLT-2 inhibitors by HPLC in Its API and Dosage Form
    308. Cardiometabolic Risk Reduction: A Review of Clinical Guidelines and the Role of SGLT-2 inhibitors
    309. Euglycemic Diabetic Ketoacidosis, SGLT-2 inhibitors and COVID-19; The Murphy Law of COVID-19
    310. Development of Efficient Routes to Access C-Glycosides as SGLT-2 inhibitors for the Treatment of Type 2 Diabetes
    311. Current Utilization Trends of SGLT-2 inhibitors in Type 2 Diabetics With Heart Failure
    312. SGLT-2 inhibitors for people with type 2 diabetes
    313. The placebo response of injectable GLP‐1 receptor agonists vs. oral DPP‐4 inhibitors and SGLT‐2 inhibitors: a systematic review and meta‐analysis
    314. SGLT-2 inhibitors: A new era in managing diabetic kidney disease starts now
    315. SGLT-2 inhibitors: a novelty in the treatment of type 2 diabetes
    316. P2482 Sex-based differences in cardioprotective role of SGLT-2 inhibitors in patients with type 2 diabetes mellitus
    317. Correlations Between SGLT-2 inhibitors and Acute Renal Failure by Signal Detection Using FAERS: Stratified Analysis for Reporting Country and Concomitant Drugs
    318. Expect the Unexpected: SGLT-2 inhibitors in the Treatment of Type 2 Diabetes and/or Heart Failure
    319. Analysis of Adverse Drug Reactions Induced by SGLT-2 inhibitors
    320. SGLT-2 inhibitors in heart failure: An updated systematic review and meta-analysis of 13 randomized clinical trials including 14618 patients with heart failure.
    321. SGLT-2 inhibitors DEMONSTRATE CONSISTENT REDUCTION IN CARDIOVASCULAR MORTALITY AND HEART FAILURE HOSPITALIZATIONS AN UP-TO …
    322. Overview of the efficacy and safety of SGLT-2 inhibitors in type 2 diabetes mellitus
    323. The effects of sodium glucose co-transporter (SGLT) 2 inhibitors on hematocrit levels: a systematic review and meta-analysis of randomized controlled trials.
    324. Glycosuria with SGLT-2 inhibitors–a new treatment approach for type 2 diabetes mellitus
    325. SGLT-2 inhibitors and circulating progenitor cells in diabetes
    326. Improving Glucose Control in Type II Diabetes with SGLT-2 inhibitors and GLP-1 Agonists
    327. Do SGLT-2 inhibitors improve cardiovascular outcomes in patients with type 2 diabetes?
    328. SGLT-2 inhibitors for people with type 2 diabetes
    329. Kidney Outcomes With SGLT-2 inhibitors
    330. SGLT-2 inhibitors and nephroprotection: a systematic review and meta-analysis
    331. SGLT-2 inhibitors-are they to stay?
    332. SGLT-2 inhibitors as adjunct therapy in type 1 diabetes: reason for hope and caution
    333. The method of reporting hypoglycemia in randomized control trials (RCTs): a systematic review on RCTs conducted for SGLT-2 inhibitors
    334. SGLT-2 inhibitors: The glucosuric antidiabetics
    335. SYSTEMATIC REVIEW OF COST-EFFECTIVENESS OF SGLT-2 inhibitors IN TYPE 2 DIABETES MELLITUS
    336. SGLT-2-inhibitors in Heart Failure
    337. SGLT 2 inhibitors: a new therapeutic target and its role in current clinical practice
    338. Renoprotective effect of SGLT-2 inhibitors vs​ ACE inhibitors in type 2 diabetes (presentation)
    339. Renoprotective effect of SGLT-2 inhibitors vs​ ACE inhibitors in type 2 diabetes
    340. FO042 EFFECT OF SGLT-2 inhibitors ON AMBULATORY BLOOD PRESSURE: DOSE-RESPONSE META-ANALYSIS AND COMPARATIVE EVALUATION WITH …
    341. Need of the hour: pharmacovigilance study of SGLT-2 inhibitors
    342. PDB13-SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS OF SGLT-2 inhibitors AND METFORMIN AS ADD-ON TO INSULIN FOR THE …
    343. Diabetes Management and Cardiovascular Risk: Are SGLT-2 inhibitors the Safest?
    344. The effect of SGLT-2 inhibitors on albuminuria and proteinuria in Diabetes Mellitus: a systematic review and meta–analysis of randomized controlled trials
    345. Falls and SGLT-2 inhibitors in geriatric patients—A
    346. SGLT 2 inhibitors improve cardiorenal outcomes in DM2–get rid of the sugar
    347. A meta-analysis of the effect of sodium glucose cotransporter-2 inhibitors (SGLT-2is) on metabolic parameters in patients with polycystic ovary syndrome (PCOS …
    348. MON-LB029 The Influence of SGLT-2 inhibitors and Other Glucose-Lowering Therapies on All-Cause Mortality Risk and Cardiovascular Outcomes in Older Patients …
    349. KETOACIDOSIS GENERATED BY TREATMENT WITH SGLT-2 inhibitors–A CASE REPORT
    350. Victoza®(liraglutide) provides greater glycaemic control than SGLT-2 inhibitors
    351. A Meta-Analysis of the Effects of SGLT-2 inhibitors on Serum Electrolytes
    352. Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials
    353. REAL WORLD SAFETY AND EFFICACY OF SGLT-2 inhibitors IN ELDERLY TYPE 2 DIABETIC PATIENTS
    354. The Influence of SGLT-2 inhibitors and Other Glucose-Lowering Therapies on Mortality Risk in Elderly Patients with Type 2 Diabetes
    355. Comparison of the effects of SGLT 2 inhibitors and sulfonylurea on electrocardiographic parameters
    356. Prescribing patterns of SGLT-2 inhibitors and GLP-1 agonist in patients with both DM and ASCVD
    357. SGLT-2 inhibitors
    358. TREATMENT WITH SGLT-2 inhibitors IN PATIENTS WITH DIABETES MELLITUS AND ESSENTIAL HYPERTENSION–DYNAMIC OF BLOOD PRESSURE VISIT-TO …
    359. Use of SGLT-2 inhibitors in Patients with Chronic Kidney Disease.
    360. Effect of SGLT-2 inhibitors on Cardiovascular Outcomes Among Patients With Heart Failure and Type 2 Diabetes Mellitus: A Systemic Review and Meta …
    361. Effects of SGLT-2 inhibitors and Visceral Fat on Glucose Metabolism
    362. SGLT-2 inhibitors and amputation: A real or an overestimated risk?
    363. SGLT-2 inhibitors: a new therapy for diabetes
    364. SGLT-2 inhibitors as adjunctive therapy in type 1 diabetes: Short experience from a center
    365. SGLT-2 inhibitors: An Evidence-Based Perspective
    366. Advances in cardiovascular safety of SGLT-2 inhibitors and GLP-1 receptor agonists
    367. A Multivariate Safety and Efficacy Analysis of Prescribing Information for Next Generation SGLT-2 inhibitors in Type 2 Diabetes Treatment
    368. SGLT-2 inhibitors in type 2 diabetes-protecting the kidney (and heart) beyond glucose control
    369. WHAT PHYSICIANS NEED TO KNOW ABOUT SGLT-2 inhibitors
    370. Cerebrovascular Complications of Diabetes: SGLT-2 inhibitors as a Promising Future Therapeutics.
    371. SGLT-2 inhibitors–aT The LimiTS
    372. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
    373. SGLT inhibitor adjunct therapy in type 1 diabetes
    374. Contribution of hyperglycemia on diabetic complications in obese type 2 diabetic SDT fatty rats: effects of SGLT inhibitor phlorizin
    375. Sodium-glucose co-transporter (SGLT) inhibitor restores lost axonal varicosities of the myenteric plexus in a mouse model of high-fat diet-induced obesity
    376. Optimizing SGLT inhibitor treatment for diabetes with chronic kidney diseases
    377. Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers
    378. Pharmacological investigations on efficacy of Phlorizin a sodium-glucose co-transporter (SGLT) inhibitor in mouse model of intracerebroventricular streptozotocin …
    379. Modeling effects of SGLT‐2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes
    380. Restoration of the Attenuated Neuroprotective Effect of Ischemic Postconditioning in Diabetic Mice by SGLT inhibitor Phlorizin
    381. The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE−/− mice
    382. 24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized …
    383. DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects
    384. Interaction of the sodium/glucose cotransporter (SGLT) 2 inhibitor canagliflozin with SGLT1 and SGLT2: inhibition kinetics, sidedness of action, and transporter …
    385. Glycemic effects of SGLT-2 inhibitor Canagliflozin in type 1 diabetes patients using the dexcom G4 platinum CGM
    386. Consensus Report on Diabetic Ketoacidosis and Adjunctive SGLT inhibitor Therapy in Type 1 Diabetes
    387. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with …
    388. Effects of the SGLT-2 inhibitor empagliflozin on renal tissue oxygenation in non-diabetic subjects: a randomized, double-blind, placebo-controlled study …
    389. Novel SGLT inhibitor (SGL5094) Improves Postprandial Hyperglycemia Through the Suppression of SGLT1-Mediated Glucose Transport Across the Small Intestine.
    390. Anti-inflammatory effect for atherosclerosis progression by sodium-glucose cotransporter 2 (SGLT-2) inhibitor in a normoglycemic rabbit model
    391. … , tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, in healthy Japanese …
    392. Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
    393. Efficient Synthesis of Empagliflozin, an inhibitor of SGLT-2, Utilizing an AlCl3-Promoted Silane Reduction of a β-Glycopyranoside
    394. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
    395. Empagliflozin, a novel potent and selective SGLT‐2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin‐induced diabetic rats …
    396. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers
    397. Empagliflozin, SGLT 2 inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of Klotho expression
    398. Renoprotective effects of combined SGLT 2 and ACE inhibitor therapy in diabetic D ahl S rats
    399. SGLT-2 inhibitor therapy added to GLP-1 agonist therapy in the management of T2DM
    400. Effects of the sodium‐glucose cotransporter 2 (SGLT 2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats
    401. Long‐term treatment with empagliflozin, a novel, potent and selective SGLT‐2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic …
    402. Euglycaemic diabetic ketoacidosis in a 43-year-old woman with type 2 diabetes mellitus on SGLT-2 inhibitor (empagliflozin)
    403. Efficacy and safety of adding sotagliflozin, a dual sodium‐glucose co‐transporter (SGLT) 1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 …
    404. … and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor
    405. Off-target effects of sodium-glucose cotransporter 2 (SGLT-2) inhibitor in cardiovascular disease
    406. A validated LC‐MS/MS method for the determination of canagliflozin, a sodium–glucose co‐transporter 2 (SGLT‐2) inhibitor, in a lower volume of rat plasma …
    407. The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical …
    408. A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK-and HNF1A-MODY than in type 2 diabetes mellitus
    409. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials
    410. The sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin lowers blood pressure independent of weight or HbA1c changes
    411. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: once-weekly semaglutide versus empagliflozin
    412. Canagliflozin, an SGLT-2 inhibitor, ameliorates acetic acid-induced colitis in rats through targeting glucose metabolism and inhibiting NOX2
    413. Very low carbohydrate diet and SGLT-2-inhibitor: double jeopardy in relation to ketoacidosis
    414. A quantitative LC–MS/MS method for determining ipragliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, and its application to a pharmacokinetic study in …
    415. Effect of a selective SGLT 2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats
    416. Back off to better blow up: acute GFR decrease at SGLT-2 inhibitor initiation
    417. SGLT2 inhibitor-induced euglycaemic diabetic ketoacidosis may be due to abrupt, severe and transient impaired glucose sensing in susceptible individuals …
    418. Factors associated with A1C reduction with GLP-1 agonist or SGLT-2 inhibitor use
    419. Liraglutide and dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational …
    420. SGLT-2 inhibitor intervention in diabetes mellitus patients can reduce the incidence of renal injury and adverse events
    421. SGLT‐2 inhibitor Renal Outcome Modification in Type‐2 Diabetes: Evidence from Studies in Patients with High or Low Renal Risk
    422. Profile of Ipragliflozin, an Oral SGLT-2 inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date
    423. Fournier’s gangrene under SGLT-2 inhibitor therapy: A literature review and case report
    424. Synthesis of SGLT-2 inhibitor Empagliflozin
    425. Invited review. Series: Implications of the recent CVOTs in type 2 diabetes: Which patients for GLP-1RA or SGLT-2 inhibitor?
    426. 442: Diagnosis and Management of SGLT-2 inhibitor-Induced Euglycemic DKA After Cardiac Surgery
    427. Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus
    428. A practical stereoselective synthesis and novel cocrystallizations of an amphiphatic SGLT-2 inhibitor
    429. The SGLT-2 inhibitor empagliflozin preserves beta cell mass and restores glucose homeostasis in the male diabetic ZDF rat
    430. US Prevalence of Individuals With Diabetes and Chronic Kidney Disease Indicated for SGLT-2 inhibitor Therapy
    431. Ertugliflozin: a new option in the SGLT-2 inhibitor market for the treatment of type 2 diabetes mellitus
    432. Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: a …
    433. Euglycaemic diabetic ketoacidosis in a 43-year-old woman with type 2 diabetes mellitus on SGLT-2 inhibitor (empagliflozin)
    434. Excess weight loss in a patient with type 2 diabetes mellitus treated with an SGLT-2 inhibitor
    435. Abstract# 1040609: SGLT-2 inhibitor Prescribing Patterns at Tertiary Care Diabetes Center for Individuals with Diabetes and Heart Failure
    436. … for cost-savings in the elderly Ontarian population with type 2 diabetes due to reduction in mild hypoglycemia events for SGLT-2 inhibitor versus sulfonylurea (SU) …
    437. Tubuloglomerular feedback in renal glucosuria: mimicking long-term SGLT-2 inhibitor therapy
    438. … -1 RECEPTOR AGONIST AND SGLT-2 inhibitor COMBINATION ON BLOOD PRESSURE LEVELS COMPARED TO SGLT-2 inhibitor ALONE: A SYSTEMATIC …
    439. The SGLT-2 inhibitor dapagliflozin reduces cell death and apoptosis in cardiomyocytes exposed to trastuzumab and doxorubicin through NLRP3-mediated pathways.
    440. Euglycemic diabetic ketoacidosis precipitated by SGLT-2 inhibitor use, pericarditis, and fasting: a case report
    441. Euglycemic diabetic ketoacidosis caused by a sodium-glucose co-transporter (SGLT) 2 inhibitor after coronary artery bypass grafting
    442. P722 Glycemic control with canagliflozin, a SGLT-2 inhibitor, attenuates atherosclerosis and endothelial dysfunction in diabetic apolipoprotein e-deficient mice
    443. P2295 SGLT 2 inhibitor suppresses atrial fibrillation in the canine model of atrial fibrillation
    444. … stage rapidly progressive diabetic nephropathy effectively treated with combination therapy including RAS blocker, GLP-1 receptor agonist and SGLT-2 inhibitor
    445. Novel SGLT 2 inhibitor: first‐in‐man studies of antisense compound is associated with unexpected renal effects
    446. Hypomagnesemia-Induced Hypocalcemia Successfully Treated With Sodium-Glucose Cotransport inhibitor (SGLT-2i), a Case Report
    447. Sodium Glucose Cotransporter-2 (SGLT-2) inhibitor Related Diabetic Ketoacidosis
    448. About the choice between a DPP-4 inhibitor and a SGLT 2 inhibitor tor treating type 2 diabetes
    449. Sodium-Glucose Cotransporter 2 (SGLT-2) inhibitor drugs: Assessment of safety in Fasting Diabetics
    450. Abstract# 998903: Euglycemic Relapsing Diabetic Ketaocidosis Due to SGLT-2 inhibitor Use: A Metabolic Challenge in Need of Substrate
    451. Abstract# 1000873: Euglycemic Relapsing Diabetic Ketaocidosis Due to SGLT-2 inhibitor Use: A Metabolic Challenge in Need of Substrate
    452. A promising combination for future treatment of type 2 diabetes: Coadministration of empagliflozin (SGLT-2 inhibitor) with linagliptin (DPP-4 inhibitor)
    453. Evaluation of glycemic control by metformin+ glitazone+ DPP-4 inhibitor+ SGLT-2 inhibitor combination in patients with type 2 diabetes quitting basal/bolus …
    454. US Prevalence Estimates of Individuals With Diabetes and Chronic Kidney Disease Indicated for SGLT-2 inhibitor Initiation
    455. Remogliflozin: the new low cost SGLT-2 inhibitor for type 2 diabetes mellitus
    456. Renal outcomes and all-cause death associated with SGLT-2 inhibitor versus other glucose-lowering drugs (CVD-REAL 3 Korea).
    457. Individualizing treatment with SGLT-2 inhibitor therapy in type 2 diabetes mellitus
    458. Abstract P233: Sodium Glucose Transporter Type-2 (SGLT-2) inhibitor, Empagliflozin, Improves Cardiovascular Outcomes in Female Diabetic db/db Mice Independent …
    459. Rare Infection Linked With SGLT-2 inhibitor Use
    460. Unmasking Type–1 Diabetes Mellitus Following an Episode of Euglycemic Diabetic Ketoacidosis with SGLT-2 inhibitor Use: A Case Report
    461. A case series of sodium glucose co-transporter-2 inhibitor (SGLT-2i) related diabetic ketoacidosis and literature review of the possible pathophysiology
    462. Effect of SGLT-2 inhibitor Therapy on Cardiovascular Health in Diabetes Mellitus Patients
    463. Two clinical cases of adjunctive use of a SGLT-2 inhibitor in type 1 diabetes
    464. SUN-180 Successful Use of SGLT-2 inhibitor Dapagliflozin in Three Patients with Renal Transplant and Diabetes: A Fruit for Thoughts
    465. SGLT-2 inhibitor-INDUCED DKA: UNMASKING OF LATENT AUTOIMMUNE DIABETES IN ADULTS. CAN WE DO BETTER?
    466. Use of SGLT‐2 inhibitor in COVID‐19: A cautionary tale
    467. A Case of Euglycemic DKA With SGLT 2 inhibitor Use-A Diagnostic and Therapeutic Dilemma
    468. Severe SGLT-2 inhibitor-induced euglycemic ketoacidosis-a rare but serious complication
    469. 5.1 EFFECTS OF THE SGLT-2 inhibitor EMPAGLIFLOZIN ON VASCULAR FUNCTION AND CENTRAL HEMODYNAMICS IN PATIENTS WITH TYPE 2 …
    470. … agonist; empagliflozin (Jardiance®, Boehringer Ingelheim and Eli Lilly), a SGLT-2 inhibitor; and sitagliptin (Januvia®, Merck), a DPP-4 inhibitor. However, we do …
    471. BITTER-SWEET DKA: A CASE OF SGLT-2 inhibitor INDUCED EUGLYCEMIC DKA IN A TYPE-1 DIABETIC PATIENT
    472. SGLT 2 inhibitor induced euglycemic ketoacidosis
    473. BP reduction with the sodium glucose co-transporter 2 inhibitor (SGLT-2i) empagliflozin (EMPA) in type 2 diabetes (T2D) is similar in treatment naïve as in those on …
    474. The combinatorial effective approach of alpha-glucosidase inhibitor and Sodium-glucose co-transporter 2 (SGLT-2)
    475. Post-Operative Euglycemic Diabetic Ketoacidosis in a Patient With SGLT-2 inhibitor Use and Recent Sleeve Gastrectomy
    476. First‐dose effect of the SGLT 2 inhibitor ipragliflozin on cardiovascular activity in spontaneously diabetic Torii fatty rats
    477. Fournier’s gangrene and diabetic ketoacidosis with lower-than-anticipated glucose levels associated with SGLT-2 inhibitor: A double trouble
    478. Body weight gain and hyperphagia after administration of SGLT-2 inhibitor: a case report
    479. Acute interstitial nephritis related to SGLT-2 inhibitor
    480. … mechanisms underlying the renoprotective effect of empagliflozin, a novel selective sodium glucose co-transporter (SGLT) 2 inhibitor, against diabetic nephropathy in …
    481. Functional imaging of pharmacological action of SGLT2 inhibitor ipragliflozin via PET imaging using 11C‐MDG
    482. Euglycemic Diabetic Ketoacidosis in a Patient on a SGLT-2 inhibitor Presenting with Acute Pancreatitis
    483. Pharmacokinetics, Biotransformation, Distribution and Excretion of Empagliflozin, a Sodium-Glucose Co-Transporter (SGLT 2) inhibitor
    484. Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes
    485. Short-term renoprotective effect of SGLT-2 inhibitor for renal function and albuminuria in type 2 diabetes: a retrospective study
    486. Euglycemic Diabetic Ketoacidosis With SGLT-2 inhibitor
    487. Canagliflozin, a SGLT-2 inhibitor, relieves ER stress, modulates autophagy and induces apoptosis in irradiated HepG2 cells: Signal transduction between …
    488. Effects of concomitant combination of SGLT‐2 inhibitor and GLP‐1 receptor agonist on renal outcomes in T2D with eGFR below 30 and macroalbuminuria: A case …
    489. SHOULD CARDIOLOGIST PRESCRIBE AN SGLT-2 inhibitor?
    490. Short-term renoprotective effect of SGLT-2 inhibitor for renal function and albuminuria in type 2 diabetes
    491. Acute Renal Failure With Cocaine and SGLT-2 inhibitor
    492. GLP-1RA as Add-on Therapy to SGLT-2 inhibitor
    493. Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: a …
    494. Effect of SGLT-2 inhibitor on Bone Turnover in Overweight and Obese Patients with Type 2 Diabetes
    495. Choosing an SGLT-2 inhibitor for a patient with type 2 diabetes: Which agent (if any) is best
    496. Effect of tofogliflozin, a SGLT-2 inhibitor, on diabetic ocular complications in SDT rats
    497. Identification on Anti-Atherosclerotic Mechanism of SGLT-2 inhibitor in Diabetic Rabbit Model
    498. Upregulation of Toll-Like Receptors That Underlies Diabetes-Induced Exacerbation of Cardiorenal Syndrome is Attenuated by Canagliflozin, an SGLT-2 inhibitor
    499. Effects of Combination of SGLT-2 inhibitor and GLP-1 Receptor Agonist on Renal Outcome in T2D with GFR below 30 and Macroalbuminuria: A Case Series
    500. Hyperglycemic Diabetic ketoacidosis precipitated by an SGLT-2 inhibitor in a non-insulin dependant type 2 diabetic
    501. Effects of SGLT-2 inhibitor on mitochondrial function in renal proximal tubular cell
    502. SGLT-2 inhibitor: A Unique Antidiabetic in Type 2 Diabetes Mellitus
    503. Sodium dependent glucose transporter (SGLT) 1/2-elucidating inhibitor SAR and selectivity using homology modelling and 3D QSAR studies.
    504. Euglycemic DKA after initiating an SGLT-2 inhibitor and the P90X diet
    505. Effect of dual sodium-glucose cotransporter (SGLT)-1/2 inhibitor sotagliflozin on glycemic and nonglycemic outcomes and on hypoglycemia in type 1 diabetes. A meta …
    506. Farxiga (Dapagliflozin), an Oral SGLT-2 inhibitor, a New FDA-Approved Treatment Option for Type 2 Diabetes
    507. Hydrogen-bonded structures and interaction energies in two forms of the SGLT-2 inhibitor sotagliflozin
    508. Dapagliflozin (forxiga®): SGLT 2 cotransporter inhibitor as glucose-lowering agent in type 2 diabetes
    509. Ketoacidosis with SGLT-2 inhibitor and Ketogenic Diet: A Case Study
    510. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
    511. SGLT2 inhibitors may predispose to ketoacidosis
    512. An update on the safety of SGLT2 inhibitors
    513. SGLT2 inhibitors: are they safe?
    514. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
    515. Possible adverse effects of SGLT2 inhibitors on bone
    516. A review on the relationship between SGLT2 inhibitors and cancer
    517. SGLT2 inhibitors and the diabetic kidney
    518. Risks associated with SGLT2 inhibitors: an overview
    519. SGLT2 inhibitors
    520. An update on SGLT2 inhibitors for the treatment of diabetes mellitus
    521. SGLT2 inhibitors and mechanisms of hypertension
    522. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
    523. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus
    524. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
    525. Development of SGLT1 and SGLT2 inhibitors
    526. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
    527. Effects of SGLT2 inhibitors on cardiovascular outcomes
    528. Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects
    529. SGLT2 inhibitors: their potential reduction in blood pressure
    530. SGLT2 inhibitors as a therapeutic option for diabetic nephropathy
    531. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans
    532. SGLT2 inhibitors in the treatment of type 2 diabetes
    533. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors
    534. SGLT2 inhibitors: the latest “new kids on the block”!
    535. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis
    536. SGLT2 inhibitors: molecular design and potential differences in effect
    537. Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis
    538. SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection
    539. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors
    540. SGLT2 inhibitors: benefit/risk balance
    541. Acute kidney injury from SGLT2 inhibitors: potential mechanisms
    542. Promise of SGLT2 inhibitors in heart failure: diabetes and beyond
    543. Pump, pipes, and filter: do SGLT2 inhibitors cover it all?
    544. Mechanisms and evidence for heart failure benefits from SGLT2 inhibitors
    545. Metabolism of the failing heart and the impact of SGLT2 inhibitors
    546. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30–50% of filtered glucose load in humans
    547. Lower risk of death with SGLT2 inhibitors in observational studies: real or bias?
    548. SGLT2 inhibitors in the management of type 2 diabetes
    549. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis
    550. Why do SGLT2 inhibitors inhibit only 30–50% of renal glucose reabsorption in humans?
    551. Uric acid and the cardio‐renal effects of SGLT2 inhibitors
    552. SGLT2 inhibitors-induced electrolyte abnormalities: an analysis of the associated mechanisms
    553. The potential role of SGLT2 inhibitors in the treatment of type 1 diabetes mellitus
    554. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of …
    555. SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects
    556. Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus
    557. SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management
    558. Synthetic strategies toward SGLT2 inhibitors
    559. SGLT2 inhibitors and the kidney: effects and mechanisms
    560. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis
    561. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study
    562. Practical approach to initiating SGLT2 inhibitors in type 2 diabetes
    563. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus
    564. SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence
    565. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments
    566. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease
    567. Are SGLT2 inhibitors ready for prime time for CKD?
    568. The renal effects of SGLT2 inhibitors and a mini-review of the literature
    569. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and …
    570. Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells
    571. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses
    572. Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes
    573. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity
    574. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives
    575. Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease
    576. SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System
    577. Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: a meta-analysis
    578. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
    579. SGLT2 inhibitors in type 2 diabetes management: key evidence and implications for clinical practice
    580. SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases
    581. Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations
    582. Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure
    583. The serendipitous story of SGLT2 inhibitors in heart failure: new insights from DECLARE-TIMI 58
    584. Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin
    585. SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission
    586. Mechanisms in endocrinology: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism?
    587. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials
    588. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System
    589. Does lower limb amputation concern all SGLT2 inhibitors?
    590. SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks
    591. Adverse effects of SGLT2 inhibitors on bone health
    592. Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors
    593. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications
    594. Acute kidney injury and adverse renal events in patients receiving SGLT2–inhibitors: a systematic review and meta-analysis
    595. SGLT2 inhibitors: cardiovascular benefits beyond HbA1c—translating evidence into practice
    596. SGLT2 inhibitors: nephroprotective efficacy and side effects
    597. SGLT2 inhibitors: β blockers for the kidney?
    598. Adoption of new glucose-lowering medications in the US—the case of SGLT2 inhibitors: nationwide cohort study
    599. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with …
    600. SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta‐analysis
    601. Use of SGLT2 inhibitors for diabetes and risk of infection: analysis using general practice records from the NPS MedicineWise MedicineInsight program
    602. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind …
    603. SGLT2 inhibitors in T2D and associated comorbidities—differentiating within the class
    604. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data
    605. SGLT2 inhibitors with cardiovascular benefits: transforming clinical care in type 2 diabetes mellitus
    606. SGLT2 inhibitors: glucuretic treatment for type 2 diabetes
    607. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney …
    608. The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis
    609. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus
    610. Cardiovascular and renal benefits of SGLT2 inhibitors: a narrative review
    611. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation
    612. Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice
    613. SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018)
    614. SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis
    615. Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using …
    616. Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low‐grade inflammation the neglected component?
    617. SGLT2 inhibitors and urinary tract infections
    618. Effic